Shares of Bio-Techne Corp. rallied 5.67% to $63.03 Monday, on what proved to be an all-around favorable trading session for ...

Minneapolis-based life sciences firm Bio-Techne Corp. on Wednesday said it’s reached a deal to buy Austin, Texas-based Asuragen for up to $320 million. Under the terms of the deal, Bio-Techne will pay ...

Shares of life sciences company Bio-Techne (NASDAQ:TECH) jumped 2.8% in the afternoon session after Baird adjusted its price target on the company, signaling a more positive outlook. The investment ...

MINNEAPOLIS, Sept. 24, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH), a global provider of life science tools, reagents, and diagnostic products, today released its 2025 Corporate ...

With a recent deal struck to buy B-MoGen Biotechnologies Inc., Minneapolis-based biotechnology manufacturer Bio-Techne has made its 15th acquisition within five years. Bio-Techne will acquire all ...

MINNEAPOLIS, July 15, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced a strategic partnership to distribute Spear Bio's next-generation ultrasensitive immunoassays, enabling ...

MINNEAPOLIS and TOLOCHENAZ, Switzerland, June 22, 2023 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH), a global life sciences company providing innovative tools and bioactive reagents for the ...

The end of an earnings season can be a great time to discover new stocks and assess how companies are handling the current ...

Bio-Techne (TECH) prevailed on another claim that Miltenyi Biotec KG commercialized antibodies developed based on information obtained by reverse engineering Bio-Techne’s proprietary R&D Systems ...

Bio-Techne Corp. topped $1 billion in full-year sales for the first time, its latest results showed Thursday, and the Minneapolis-based life science firm said it is beginning a two-year leadership ...

View original content to download multimedia:https://www.prnewswire.com/news-releases/bio-techne-releases-second-quarter-fiscal-2025-results-302368325.html ...

Bio-Techne Corp. will spend $257 million for a 20% stake of New Brighton company that makes cell culture devices. If financial targets are met, Bio-Techne could buy the rest of Wilson Wolf ...